Dr. Fahar Merchant reports

MEDICENNA APPOINTS DR. ARASH YAVARI AS CHAIR OF DEVELOPMENT ADVISORY COMMITTEE

Medicenna Therapeutics Corp. has appointed Dr. Arash Yavari as the chair of its development advisory committee (DAC), a team comprising industry veterans in immuno-oncology drug development and regulatory strategy.

"We are pleased to welcome Dr. Arash Yavari as the chair of our development advisory committee," said Dr. Fahar Merchant, president and chief executive officer of Medicenna. "We have been working closely with Dr. Yavari on MDNA11 for the past two years and have appreciated his considerable expertise in drug development. Dr. Yavari's contributions will be instrumental in advancing our planned phase 2 dose expansion and combination studies which are expected to commence in the third and fourth calendar quarters of this year, respectively."

Dr. Yavari stated: "I look forward to assisting Medicenna's team in their efforts to provide well-tolerated and more effective cytokine-based, precision immunotherapies such as MDNA11 to patients with difficult-to-treat cancers. The encouraging data generated to date with MDNA11 in the ongoing Ability study highlights the promise of Medicenna's innovative IL-2 superkines, bizaxofusp for recurrent glioblastoma and, more broadly, the BiSKITs platform. These novel approaches and their expected synergy with a range of other cancer treatment modalities have the potential to provide long-lasting clinical benefit to patients with advanced cancer."

Dr. Yavari is a physician-scientist with over 20 years of broad clinical, scientific and industry drug development experience. He has extensive expertise in early clinical development and scientific strategy across a range of therapeutic areas, including immuno-oncology, hemato-oncology, inflammation, autoimmunity, cardiometabolic and rare disease. Dr. Yavari is a university research lecturer and principal investigator at the Radcliffe department of medicine, University of Oxford, chief science officer of Imbria Pharmaceuticals, and serves as senior drug development clinician with Weatherden, a London-based biotech-focused consulting organization. Dr. Yavari holds a BSc and MBBS from the University of London, and a DPhil from the University of Oxford.

About Medicenna Therapeutics Corp.

Medicenna is a clinical-stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 superkines and first-in-class empowered superkines. Medicenna's long-acting IL-2 superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's IL-4 empowered superkine, bizaxofusp (formerly MDNA55), has been studied in five clinical trials including a phase 2b trial for recurrent GBM (glioblastoma multiforme), the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained fast-track and orphan drug status from the U.S. Food and Drug Administration (FDA) and the FDA/EMA (European Medicines Agency), respectively. Medicenna's early-stage BiSKITs program (bifunctional superkine immunotherapies) is designed to enhance the ability of superkines to treat immunologically cold tumours.

We seek Safe Harbor.